Cargando…

Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus

Patients with diabetes mellitus (DM) have accelerated atherosclerosis with an increased risk for atherothrombotic cardiovascular complications. A state of high platelet reactivity and activation, hypercoagulability (prothrombotic state) and a subdued response to standard antiplatelet agents may expl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Jung Hwa, Tantry, Udaya S., Gurbel, Paul A., Jeong, Young-Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411553/ https://www.ncbi.nlm.nih.gov/pubmed/25922803 http://dx.doi.org/10.4093/dmj.2015.39.2.95

Ejemplares similares

Personalized antiplatelet therapy: state of the art
por: Gurbel, Paul A, et al.
Publicado: (2012)

Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing
por: Jeong, Young-Hoon, et al.
Publicado: (2019)

State of the art: Oral antiplatelet therapy
por: Gurbel, Paul A, et al.
Publicado: (2016)

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
por: Gurbel, Paul A, et al.
Publicado: (2010)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

In Vitro Evidence for the Role of Cytokine Storm in the Generation of Stent Thrombosis in COVID-19 Patients
por: Gurbel, Paul A., et al.
Publicado: (2022)

Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can “Thrombin Pathway” Be a New Target for Therapy?
por: Kim, Hyun Kuk, et al.
Publicado: (2020)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial
por: Park, Hyun-Woong, et al.
Publicado: (2021)

Further evidence for the use of aspirin in COVID-19
por: Tantry, Udaya S., et al.
Publicado: (2022)

International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests
por: Gurbel, Paul A., et al.
Publicado: (2021)

Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences
por: Kim, Hyun Kuk, et al.
Publicado: (2021)

Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease Patients
por: Lev, Eli I., et al.
Publicado: (2014)

Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent
por: Tantry, Udaya S, et al.
Publicado: (2021)

Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations
por: Chaudhary, Rahul, et al.
Publicado: (2020)

IS THERE A ROLE FOR α1-ANTITRYPSIN IN COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

AGE-BASED RISK FACTORS FOR SYMPTOMATIC COVID-19 IN THE MINORITY POPULATION
por: Gurbel, Paul A., et al.
Publicado: (2021)

Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention
por: Jeong, Young-Hoon, et al.
Publicado: (2012)

Relationship of Platelet Reactivity With Bleeding Outcomes During Long‐Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non‐ST‐Segment Elevation Acute Coronary Syndromes
por: Cornel, Jan H., et al.
Publicado: (2016)

Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs
por: Tufano, A., et al.
Publicado: (2011)

Current status of managing diabetes mellitus in Korea
por: Ha, Kyoung Hwa, et al.
Publicado: (2016)

High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells
por: Grześk, Grzegorz, et al.
Publicado: (2013)

IS LOW DOSE ASPIRIN EFFECTIVE IN REDUCING IN-HOSPITAL CLINICAL OUTCOMES IN PATIENTS WITH COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
por: Angiolillo, Dominick J.
Publicado: (2009)

Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2012)

Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
por: Hillegass, William B, et al.
Publicado: (2011)

A review of current treatment strategies for gestational diabetes mellitus
por: Kelley, Kristi W, et al.
Publicado: (2015)

Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction
por: Kang, Min Gyu, et al.
Publicado: (2021)

Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
por: Jourdi, Georges, et al.
Publicado: (2021)

Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens
por: Heramvand, Nadia, et al.
Publicado: (2022)

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes
por: Usman, Abira, et al.
Publicado: (2022)

First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19
por: Tantry, Udaya S, et al.
Publicado: (2021)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention
por: Ahn, Jong-Hwa, et al.
Publicado: (2022)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population
por: Gurbel, Paul A., et al.
Publicado: (2021)

Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy
por: Balasubramaniam, Karthik, et al.
Publicado: (2012)

Antiplatelet drugs in cardiological practice: Established strategies and new developments
por: Krötz, Florian, et al.
Publicado: (2008)

Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options
por: Fintel, Dan J
Publicado: (2012)

Remodeling adipose tissue inflammasome for type 2 diabetes mellitus treatment: Current perspective and translational strategies
por: Banerjee, Amrita, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pph3748gajk085v0bla0f68qnu